CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 41 enrolled
Drug / intervention
Sintilimab injection plus Inlyta treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04387500
NCT04387500Phase 2Unknown
CompareCT.gov

Single-arm Phase II Clinical Trial to Evaluate the Initial Efficacy and Safety of Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

West China Hospital·interventional·Posted May 14, 2020·Updated Apr 9, 2024

In Brief

A Phase 2 clinical trial evaluating Sintilimab injection plus Inlyta treatment for Carcinoma, Renal Cell and 2 related conditions. Targeting 41 participants across 1 site.

Detailed Summary

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedMay 14, 2020
Enrollment StartJul 1, 2021
Primary CompletionMar 1, 2025
Study CompletionJan 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 6.1 years ago

Interventions

Sintilimab injection plus Inlyta treatmentdrug

Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC